Effectiveness of Non-CPAP Sleep Apnea Therapy

USA: The American Academy of Dental Sleep Medicine (AADSM) Annual Meeting has been a platform for groundbreaking research in the field of sleep apnea treatment. This year, several independent scientific abstracts featured data utilizing precision oral devices from ProSomnus, Inc., a leading provider of non-CPAP (Continuous Positive Airway Pressure) Obstructive Sleep Apnea (OSA) therapy.

Award-Winning Study

Among the presented abstracts, one study, titled “Overall Clinical Effectiveness of Oral Appliance Therapy as a First-Line Treatment Option Compared with Continuous Positive Airway Pressure in Patients with Moderate to Severe Obstructive Sleep Apnea: The FLOSAT Study,” received the prestigious 2024 AADSM Clinical Excellence Award. This study, conducted by researchers from the University of Antwerp and Antwerp University Hospital, compared the efficacy of custom-made, titratable mandibular advancement devices (MADs) from ProSomnus (EVO®) with CPAP therapy.

Innovative Sleep Apnea Treatment Utilising Oral Appliances by Dr Erin Sundt

According to the data, ProSomnus EVO® devices demonstrated “significantly higher patient preference and at least non-inferior overall clinical effectiveness to CPAP therapy.” Marijke Dieltjens, one of the study’s authors, stated, “The data from the FLOSAT study indicate that OSA therapy with ProSomnus EVO devices is safe, effective, and better adhered to than CPAP.”

Debunking Myths About Severe OSA

Another abstract, titled “Incidence of Adverse Effects with Mandibular Advancement Device Therapy and Impact on Treatment Modality Choice in Patients Diagnosed with Severe Obstructive Sleep Apnea,” addressed the efficacy of MADs in treating severe OSA. The analysis found comparable rates of adverse effects and levels of mandibular protrusion in patients with moderate and severe OSA, challenging the misconception that MADs are ineffective for severe cases.

As Shouresh Charkhandeh, one of the authors, explained, “The findings underscore the significance of exploring safe and effective alternatives to CPAP for severe OSA and debunking myths surrounding the efficacy of MAD in this patient population.”

Virtual Workflow and Telemedicine

Two additional abstracts presented at the AADSM Annual Meeting focused on the efficacy of ProSomnus oral appliance therapy (OAT) in a virtual workflow. The first study, conducted by BlueSleep, a virtual sleep apnea diagnosis and treatment provider, evaluated the effectiveness of ProSomnus OAT in 1,245 patients with varying levels of OSA severity. Patients received virtual consultations, home sleep tests, and remote device fitting assistance from BlueSleep dentists.

The second study compared the initial fitting of ProSomnus devices either in a virtual or in-person workflow, finding no significant differences in outcomes between the two groups. Dr. Jordan Stern, CEO and Founder of BlueSleep, noted, “Results of these studies confirm that the BlueSleep virtual workflow using the most advanced oral appliance therapy from ProSomnus can help increase availability of treatment to the one billion globally suffering from obstructive sleep apnea, including those who cannot tolerate or have failed treatment with CPAP.”

Industry Perspective

Len Liptak, Chief Executive Officer of ProSomnus Sleep Technologies, expressed pride in the company’s precision devices being included in high-quality scientific research. He stated, “Research and clinical practice demonstrate that ProSomnus precision oral devices are highly effective, associated with high levels of adherence, have an excellent safety record, and are covered by most medical insurances and Medicare.”

As the field of sleep apnea treatment continues to evolve, these research findings highlight the potential of non-CPAP therapies, such as ProSomnus precision oral devices, in providing effective and well-tolerated treatment options for patients with OSA.